Octave® Bioscience, Inc. Announces Publication in Nature Communications
Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.
- Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.
- Octave’s studies featured in the manuscript included world-class cohorts including CLIMB from Brigham and Women’s, EPIC from UCSF, and the Accelerated Cure Project Biorepository.
- This work preceded and made possible the analytical and clinical validation studies for Octave’s multi-protein biomarker test, Multiple Sclerosis Disease Activity (MSDA), which were both previously published.
- In addition, the research indicates multi-protein models have stronger associations than any single protein models.